Singapore eDevelopment (SGX:40V) biomedical subsidiary confirms LB2 efficacy against Ebola
- Written by ACN Newswire
SINGAPORE, Mar 1, 2018 - (ACN Newswire) - Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker, which is designed to combat a range of...